title: Results with cyclosporine in renal transplantation in patients who have lost two previous allografts.
abstract: We investigated the fate of the cadaver renal transplant done with cyclosporine and prednisone immunosuppression into a recipient who had suffered the loss of at least two prior allografts. Nineteen cadaver renal allografts were transplanted into 18 recipients. All 18 recipients had previously rejected at least two prior allografts. One of these rejected an allograft done at our institution with cyclosporine and prednisone and was included a second time in this series when a fourth allograft was received. Nine of 19 allografts were successfully transplanted. Average follow-up time was 39 months. Eight allografts were rejected. One graft was lost to technical complications. In one instance, the recipient died with a functioning graft. Duration of function of previous allografts was not found to be a critical determinant of third or fourth graft survival. Human leukocyte antigen matching was not a statistically significant determinant. Panel reactive antibody was higher in those who rejected the third or fourth allograft, but not with statistical significance. Recipients with the blood type A were less likely to enjoy successful third or fourth cadaver renal transplantation. We concluded that the "two time loser" renal allograft recipient should not be systematically denied subsequent transplantation.
authors.forename: J S
authors.initials: JS
authors.lastname: Ladowski
authors.forename: J T
authors.initials: JT
authors.lastname: Rosenthal
authors.forename: R J
authors.initials: RJ
authors.lastname: Taylor
authors.forename: T E
authors.initials: TE
authors.lastname: Starzl
authors.forename: B
authors.initials: B
authors.lastname: Carpenter
authors.forename: R
authors.initials: R
authors.lastname: Gordon
authors.forename: S
authors.initials: S
authors.lastname: Iwatsuki
authors.forename: T R
authors.initials: TR
authors.lastname: Hakala
mesh_terms: D002102:Cadaver; D003524:Cyclosporins / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects*; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D011241:Prednisone / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D003524:Cyclosporins; D011241:Prednisone